Cargando…

Percutaneous Left Atrial Appendage Closure With a Novel LAA Occluder for Stroke Prevention in Atrial Fibrillation

BACKGROUND: More than 90% of thromboses originate from the left atrial appendage (LAA) in patients with nonvalvular atrial fibrillation (NVAF). OBJECTIVES: This study was designed to investigate the safety and efficacy of LAA closure with the Leftear device (Pulse Scientific) in NVAF patients. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaochun, Hou, Shiqiang, Liu, Weijing, Chen, Wei, Chen, Fadong, Ma, Wei, Wang, Jian’an, Fan, Youqi, Wang, Yan, Chang, Dong, Fu, Hua, Cai, Heng, Zhang, Yushun, Hou, Cody R., Xu, Yawei, Zhou, Daxin, Ge, Junbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743450/
https://www.ncbi.nlm.nih.gov/pubmed/36518725
http://dx.doi.org/10.1016/j.jacasi.2022.04.009
_version_ 1784848728041979904
author Zhang, Xiaochun
Hou, Shiqiang
Liu, Weijing
Chen, Wei
Chen, Fadong
Ma, Wei
Wang, Jian’an
Fan, Youqi
Wang, Yan
Chang, Dong
Fu, Hua
Cai, Heng
Zhang, Yushun
Hou, Cody R.
Xu, Yawei
Zhou, Daxin
Ge, Junbo
author_facet Zhang, Xiaochun
Hou, Shiqiang
Liu, Weijing
Chen, Wei
Chen, Fadong
Ma, Wei
Wang, Jian’an
Fan, Youqi
Wang, Yan
Chang, Dong
Fu, Hua
Cai, Heng
Zhang, Yushun
Hou, Cody R.
Xu, Yawei
Zhou, Daxin
Ge, Junbo
author_sort Zhang, Xiaochun
collection PubMed
description BACKGROUND: More than 90% of thromboses originate from the left atrial appendage (LAA) in patients with nonvalvular atrial fibrillation (NVAF). OBJECTIVES: This study was designed to investigate the safety and efficacy of LAA closure with the Leftear device (Pulse Scientific) in NVAF patients. METHODS: A prospective, multicenter, registry-based study was conducted in 200 NVAF patients with CHA(2)DS(2)-VASc (congestive heart failure, hypertension, age, diabetes, previous stroke/transient ischemic attack, vascular disease, female sex) scores ≥2. The primary safety endpoint was defined as any serious adverse events. Efficacy was assessed by a primary composite endpoint of hemorrhagic or ischemic stroke, systemic embolism, and cardiac or unexplained death at 1 year of follow-up. RESULTS: The device was implanted in 196 patients, with 1-stop LAA closure combined with atrial fibrillation ablation implemented in 133 patients. The immediate success rate was 100%. There were serious adverse events in 9 patients (4.5%; 95% CI: 1.6%-7.4%), which mainly occurred in 1-stop LAA closure. All pericardial tamponades occurred in 6 patients with 1-stop LAA closure. No patient experienced a major bleeding event or acute device-related thrombus. During the 12-month follow-up period, the risk of the primary composite endpoint was 1.6% (95% CI: 0.3%-4.5%), and statistical noninferiority was achieved (the upper bound of 95% CI: 4.5% < the prespecified maximum annual incidence of 8.0%). Ischemic stroke occurred in 1 patient, 3 patients had incomplete LAA sealing, and no delayed device-related thrombus was found. CONCLUSIONS: LAA closure with the novel disc-like occluder shows high procedural success, satisfactory safety, and encouraging efficacy for stroke prevention in patients with NVAF. Compared with 1-stop LAA closure, single LAA closure may be more tolerable. (A multicenter, single-arm clinical trial to evaluate the efficacy and safety of left atrial appendage system for left atrial appendage occlusion in patients with non-valvular atrial fibrillation; ChiCTR1900023035)
format Online
Article
Text
id pubmed-9743450
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-97434502022-12-13 Percutaneous Left Atrial Appendage Closure With a Novel LAA Occluder for Stroke Prevention in Atrial Fibrillation Zhang, Xiaochun Hou, Shiqiang Liu, Weijing Chen, Wei Chen, Fadong Ma, Wei Wang, Jian’an Fan, Youqi Wang, Yan Chang, Dong Fu, Hua Cai, Heng Zhang, Yushun Hou, Cody R. Xu, Yawei Zhou, Daxin Ge, Junbo JACC Asia Original Research BACKGROUND: More than 90% of thromboses originate from the left atrial appendage (LAA) in patients with nonvalvular atrial fibrillation (NVAF). OBJECTIVES: This study was designed to investigate the safety and efficacy of LAA closure with the Leftear device (Pulse Scientific) in NVAF patients. METHODS: A prospective, multicenter, registry-based study was conducted in 200 NVAF patients with CHA(2)DS(2)-VASc (congestive heart failure, hypertension, age, diabetes, previous stroke/transient ischemic attack, vascular disease, female sex) scores ≥2. The primary safety endpoint was defined as any serious adverse events. Efficacy was assessed by a primary composite endpoint of hemorrhagic or ischemic stroke, systemic embolism, and cardiac or unexplained death at 1 year of follow-up. RESULTS: The device was implanted in 196 patients, with 1-stop LAA closure combined with atrial fibrillation ablation implemented in 133 patients. The immediate success rate was 100%. There were serious adverse events in 9 patients (4.5%; 95% CI: 1.6%-7.4%), which mainly occurred in 1-stop LAA closure. All pericardial tamponades occurred in 6 patients with 1-stop LAA closure. No patient experienced a major bleeding event or acute device-related thrombus. During the 12-month follow-up period, the risk of the primary composite endpoint was 1.6% (95% CI: 0.3%-4.5%), and statistical noninferiority was achieved (the upper bound of 95% CI: 4.5% < the prespecified maximum annual incidence of 8.0%). Ischemic stroke occurred in 1 patient, 3 patients had incomplete LAA sealing, and no delayed device-related thrombus was found. CONCLUSIONS: LAA closure with the novel disc-like occluder shows high procedural success, satisfactory safety, and encouraging efficacy for stroke prevention in patients with NVAF. Compared with 1-stop LAA closure, single LAA closure may be more tolerable. (A multicenter, single-arm clinical trial to evaluate the efficacy and safety of left atrial appendage system for left atrial appendage occlusion in patients with non-valvular atrial fibrillation; ChiCTR1900023035) Elsevier 2022-09-06 /pmc/articles/PMC9743450/ /pubmed/36518725 http://dx.doi.org/10.1016/j.jacasi.2022.04.009 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original Research
Zhang, Xiaochun
Hou, Shiqiang
Liu, Weijing
Chen, Wei
Chen, Fadong
Ma, Wei
Wang, Jian’an
Fan, Youqi
Wang, Yan
Chang, Dong
Fu, Hua
Cai, Heng
Zhang, Yushun
Hou, Cody R.
Xu, Yawei
Zhou, Daxin
Ge, Junbo
Percutaneous Left Atrial Appendage Closure With a Novel LAA Occluder for Stroke Prevention in Atrial Fibrillation
title Percutaneous Left Atrial Appendage Closure With a Novel LAA Occluder for Stroke Prevention in Atrial Fibrillation
title_full Percutaneous Left Atrial Appendage Closure With a Novel LAA Occluder for Stroke Prevention in Atrial Fibrillation
title_fullStr Percutaneous Left Atrial Appendage Closure With a Novel LAA Occluder for Stroke Prevention in Atrial Fibrillation
title_full_unstemmed Percutaneous Left Atrial Appendage Closure With a Novel LAA Occluder for Stroke Prevention in Atrial Fibrillation
title_short Percutaneous Left Atrial Appendage Closure With a Novel LAA Occluder for Stroke Prevention in Atrial Fibrillation
title_sort percutaneous left atrial appendage closure with a novel laa occluder for stroke prevention in atrial fibrillation
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743450/
https://www.ncbi.nlm.nih.gov/pubmed/36518725
http://dx.doi.org/10.1016/j.jacasi.2022.04.009
work_keys_str_mv AT zhangxiaochun percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation
AT houshiqiang percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation
AT liuweijing percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation
AT chenwei percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation
AT chenfadong percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation
AT mawei percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation
AT wangjianan percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation
AT fanyouqi percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation
AT wangyan percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation
AT changdong percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation
AT fuhua percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation
AT caiheng percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation
AT zhangyushun percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation
AT houcodyr percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation
AT xuyawei percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation
AT zhoudaxin percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation
AT gejunbo percutaneousleftatrialappendageclosurewithanovellaaoccluderforstrokepreventioninatrialfibrillation